trending Market Intelligence /marketintelligence/en/news-insights/trending/kojflsxda4cUsqVM606bDA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Boehringer, Pharmaxis discontinue development of drug for liver disease

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Boehringer, Pharmaxis discontinue development of drug for liver disease

Boehringer Ingelheim GmbH and Pharmaxis Ltd. discontinued the development of BI 1467335 for the treatment of nonalcoholic steatohepatitis, or NASH.

The decision to discontinue the development of the drug is based from the results of a phase 1 trial, which showed that patients with NASH were at risk of drug interactions, a situation when one drug among a combination of drugs alters the effect of another. Such interactions can result in decreased therapeutic benefits and adverse effects.

NASH is a form of nonalcoholic fatty liver disease in which the liver is inflamed and liver cells are damaged. Scarring of the liver causes it to malfunction, and serious complications include bleeding, organ failure and cancer.

Boehringer said the company will continue the ongoing phase 2 trial of BI 1467335 to treat diabetic retinopathy and expects to report results in the second half of 2020. Diabetic retinopathy is a medical condition in which damage occurs to the blood vessels in the retina due to diabetes.

Boehringer acquired BI 1467335 from South Wales, Australia-based Pharmaxis in 2015.